|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G,
Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M,
Nippgen J and Rougier P: Cetuximab and chemotherapy as initial
treatment for metastatic colorectal cancer. N Engl J Med.
360:1408–1417. 2009.PubMed/NCBI
|
|
3.
|
Bokemeyer C, Van Cutsem E, Rougier P,
Ciardiello F, Heeger S, Schlichting M, Celik I and Köhne CH:
Addition of cetuximab to chemotherapy as first-line treatment for
KRAS wild-type metastatic colorectal cancer: pooled analysis of the
CRYSTAL and OPUS randomised clinical trials. Eur J Cancer.
48:1466–1475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Daigo Y and Nakamura Y: From cancer
genomics to thoracic oncology: discovery of new biomarkers and
therapeutic targets for lung and esophageal carcinoma. Gen Thorac
Cardiovasc Surg. 56:43–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Daigo Y, Takano A, Teramoto K, Chung S and
Nakamura Y: A systematic approach to the development of novel
therapeutics for lung cancer using genomic analyses. Clin Pharmacol
Ther. 94:218–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kikuchi T, Daigo Y, Katagiri T, et al:
Expression profiles of non-small cell lung cancers on cDNA
microarrays: identification of genes for prediction of lymph-node
metastasis and sensitivity to anti-cancer drugs. Oncogene.
22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kakiuchi S, Daigo Y, Ishikawa N, et al:
Prediction of sensitivity of advanced non-small cell lung cancers
to gefitinib (Iressa, ZD1839). Hum Mol Genet. 13:3029–3043. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kikuchi T, Daigo Y, Ishikawa N, et al:
Expression profiles of metastatic brain tumor from lung
adenocarcinomas on cDNA microarray. Int J Oncol. 28:799–805.
2006.PubMed/NCBI
|
|
9.
|
Taniwaki M, Daigo Y, Ishikawa N, et al:
Gene expression profiles of small-cell lung cancers: molecular
signatures of lung cancer. Int J Oncol. 29:567–575. 2006.PubMed/NCBI
|
|
10.
|
Yamabuki T, Daigo Y, Kato T, et al:
Genome-wide gene expression profile analysis of esophageal squamous
cell carcinomas. Int J Oncol. 28:1375–1384. 2006.PubMed/NCBI
|
|
11.
|
Suzuki C, Daigo Y, Kikuchi T, Katagiri T
and Nakamura Y: Identification of COX17 as a therapeutic target for
non-small cell lung cancer. Cancer Res. 63:7038–7041.
2003.PubMed/NCBI
|
|
12.
|
Kato T, Daigo Y, Hayama S, et al: A novel
human tRNA-dihydrouridine synthase involved in pulmonary
carcinogenesis. Cancer Res. 65:5638–5646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Furukawa C, Daigo Y, Ishikawa N, et al:
Plakophilin 3 oncogene as prognostic marker and therapeutic target
for lung cancer. Cancer Res. 65:7102–7110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Suzuki C, Daigo Y, Ishikawa N, et al: ANLN
plays a critical role in human lung carcinogenesis through the
activation of RHOA and by involvement in the phosphoinositide
3-kinase/AKT pathway. Cancer Res. 65:11314–11325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Takahashi K, Furukawa C, Takano A, et al:
The neuromedin U-growth hormone secretagogue receptor
1b/neurotensin receptor 1 oncogenic signaling pathway as a
therapeutic target for lung cancer. Cancer Res. 66:9408–9419. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hayama S, Daigo Y, Kato T, et al:
Activation of CDCA1-KNTC2, members of centromere protein complex,
involved in pulmonary carcinogenesis. Cancer Res. 66:10339–10348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kato T, Hayama S, Yamabuki T, et al:
Increased expression of IGF-II mRNA-binding protein 1 is associated
with the tumor progression in patients with lung cancer. Clin
Cancer Res. 13:434–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hayama S, Daigo Y, Yamabuki T, et al:
Phosphorylation and activation of cell division cycle associated 8
by aurora kinase B plays a significant role in human lung
carcinogenesis. Cancer Res. 67:4113–4122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Taniwaki M, Takano A, Ishikawa N, et al:
Activation of KIF4A as a prognostic biomarker and therapeutic
target for lung cancer. Clin Cancer Res. 13:6624–6631. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Kato T, Sato N, Hayama S, et al:
Activation of holliday junction recognizing protein involved in the
chromosomal stability and immortality of cancer cells. Cancer Res.
67:8544–8553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Kato T, Sato N, Takano A, et al:
Activation of placenta-specific transcription factor distal-less
homeobox 5 predicts clinical outcome in primary lung cancer
patients. Clin Cancer Res. 14:2363–2370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Dunleavy EM, Roche D, Tagami H, et al:
HJURP is a cell-cycle-dependent maintenance and deposition factor
of CENP-A at centromeres. Cell. 137:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hirata D, Yamabuki T, Miki D, et al:
Involvement of epithelial cell transforming sequence 2 (ECT2)
oncoantigen in lung and esophageal cancer progression. Clin Cancer
Res. 15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sato N, Koinuma J, Fujita M, et al:
Activation of WD repeat and high-mobility group box DNA binding
protein 1 in pulmonary and esophageal carcinogenesis. Clin Cancer
Res. 16:226–239. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Nguyen MH, Koinuma J, Ueda K, et al:
Phosphorylation and activation of cell division cycle associated 5
by mitogen-activated protein kinase play a crucial role in human
lung carcinogenesis. Cancer Res. 70:5337–5347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Aragaki M, Takahashi K, Akiyama H, et al:
Characterization of a cleavage stimulation factor, 3′ pre-RNA,
subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer.
Clin Cancer Res. 7:5889–5900. 2011.
|
|
27.
|
Masuda K, Takano A, Oshita H, et al:
Chondrolectin is a novel diagnostic biomarker and a therapeutic
target for lung cancer. Clin Cancer Res. 17:7712–7722. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Fujitomo T, Daigo Y, Matsuda K, Ueda K and
Nakamura Y: Critical function for nuclear envelope protein TMEM209
in human pulmonary carcinogenesis. Cancer Res. 72:4110–4118. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Oshita H, Nishino R, Takano A, et al:
RASEF is a novel diagnostic biomarker and a therapeutic target for
lung cancer. Mol Cancer Res. 11:937–951. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ishikawa N, Daigo Y, Yasui W, et al: ADAM8
as a novel serological and histochemical marker for lung cancer.
Clin Cancer Res. 10:8363–8370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ishikawa N, Daigo Y, Takano A, et al:
Increases of amphiregulin and transforming growth factor-alpha in
serum as predictors of poor response to gefitinib among patients
with advanced non-small cell lung cancers. Cancer Res.
65:9176–9184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yamabuki T, Takano A, Hayama S, et al:
Dickkopf-1 as a novel serologic and prognostic biomarker for lung
and esophageal carcinomas. Cancer Res. 67:2517–2525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ishikawa N, Takano A, Yasui W, et al:
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a
serologic biomarker and a therapeutic target for lung and
esophageal carcinomas. Cancer Res. 67:11601–11611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Takano A, Ishikawa N, Nishino R, et al:
Identification of nectin-4 oncoprotein as a diagnostic and
therapeutic target for lung cancer. Cancer Res. 69:6694–6703. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Sato N, Yamabuki T, Takano A, et al: Wnt
inhibitor Dickkopf-1 as a target for passive cancer immunotherapy.
Cancer Res. 70:5326–5336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Nishino R, Takano A, Oshita H, et al:
Identification of Epstein-Barr virus-induced gene 3 as a novel
serum and tissue biomarker and a therapeutic target for lung
cancer. Clin Cancer Res. 17:6272–6286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Mizukami Y, Kono K, Daigo Y, et al:
Detection of novel cancer-testis antigen-specific T-cell responses
in TIL, regional lymph nodes, and PBL in patients with esophageal
squamous cell carcinoma. Cancer Sci. 99:1448–1454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Harao M, Hirata S, Irie A, et al:
HLA-A2-restricted CTL epitopes of a novel lung cancer-associated
cancer testis antigen, cell division cycle associated 1, can induce
tumor-reactive CTL. Int J Cancer. 123:2616–2625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kono K, Mizukami Y, Daigo Y, et al:
Vaccination with multiple peptides derived from novel cancer-testis
antigens can induce specific T-cell responses and clinical
responses in advanced esophageal cancer. Cancer Sci. 100:1502–1509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yokomine K, Senju S, Nakatsura T, et al:
The forkhead box M1 transcription factor, as a possible
immunotherapeutic tumor-associated antigen. Int J Cancer.
126:2153–2163. 2010.
|
|
42.
|
Tomita Y, Imai K, Senju S, et al: A novel
tumor-associated antigen, cell division cycle 45-like can induce
cytotoxic T lymphocytes reactive to tumor cells. Cancer Sci.
102:697–705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Kaneko N, Miura K, Gu Z, Karasawa H,
Ohnuma S, Sasaki H, Tsukamoto N, Yokoyama S, Yamamura A, Nagase H,
Shibata C, Sasaki I and Horii A: siRNA-mediated knockdown against
CDCA1 and KNTC2, both frequently overexpressed in colorectal and
gastric cancers, suppresses cell proliferation and induces
apoptosis. Biochem Biophys Res Commun. 390:1235–1240. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
van Duin M, Broyl A, de Knegt Y,
Goldschmidt H, Richardson PG, Hop WC, van der Holt B,
Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS and Sonneveld
P: Cancer testis antigens in newly diagnosed and relapse multiple
myeloma: prognostic markers and potential targets for
immunotherapy. Haematologica. 96:1662–1669. 2011.PubMed/NCBI
|
|
45.
|
DeLuca JG, Moree B, Hickey JM, Kilmartin
JV and Salmon ED: hNuf2 inhibition blocks stable
kinetochore-microtubule attachment and induces mitotic cell death
in HeLa cells. J Cell Biol. 159:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
DeLuca JG, Howell BJ, Canman JC, Hickey
JM, Fang G and Salmon ED: Nuf2 and Hec1 are required for retention
of the checkpoint proteins Mad1 and Mad2 to kinetochores. Curr
Biol. 13:2103–2109. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Liu D, Ding X, Du J, Cai X, Huang Y, Ward
T, Shaw A, Yang Y, Hu R, Jin C and Yao X: Human NUF2 interacts with
centromere-associated protein E and is essential for a stable
spindle microtubule-kinetochore attachment. J Biol Chem.
282:21415–21424. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Kimura M, Yoshioka T, Saio M, Banno Y,
Nagaoka H and Okano Y: Mitotic catastrophe and cell death induced
by depletion of centrosomal proteins. Cell Death Dis. 4:e6032013.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Keen N and Taylor S: Aurora-kinase
inhibitors as anticancer agents. Nat Rev Cancer. 4:927–936. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Jang YJ, Kim YS and Kim WH: Oncogenic
effect of Polo-like kinase 1 expression in human gastric
carcinomas. Int J Oncol. 29:589–594. 2006.PubMed/NCBI
|
